PURPOSE: To review the tolerability and diagnostic effectiveness of gadoteric acid under daily practice conditions in the general population and at-risk patients. MATERIALS AND METHODS: A total of 84,621 patients (45.4% men, 54.6% women, mean age 52.0 ± 16.9 years) were studied in 129 German centers. Patients underwent contrast-enhanced magnetic resonance imaging (MRI) using gadoteric acid (Gd-DOTA, Dotarem(®), Guerbet, Roissy CdG, France) as IV contrast medium (mean volume, 16.4 ml). 22.9% of the patients had at least one risk factor (e.g., allergies, previous allergic reaction to a contrast medium, and renal impairment). 554 patients received pretreatment before contrast medium administration (0.7%). Adverse events were documented and image quality was assessed. RESULTS: A diagnosis was possible in 99.7% of all cases. Image quality was rated good or excellent in 97.1%. Adverse events (e.g., nausea, vomiting, and urticaria) were observed in 0.34% of the examinations and were mostly rated as minor. There were 8 patients with serious adverse events. The adverse event rate was significantly higher in patients with a history of allergies (0.62%; p<0.001) and in patients with a previous allergic reaction to contrast medium (1.23%; p<0.001). There was no elevated incidence of adverse events in patients with renal impairment. CONCLUSION: Gadoteric acid is a well-tolerated MRI contrast medium in patients with and without risk factors that is associated with a low rate of adverse events and good or excellent image quality in most patients.
PURPOSE: To review the tolerability and diagnostic effectiveness of gadoteric acid under daily practice conditions in the general population and at-risk patients. MATERIALS AND METHODS: A total of 84,621 patients (45.4% men, 54.6% women, mean age 52.0 ± 16.9 years) were studied in 129 German centers. Patients underwent contrast-enhanced magnetic resonance imaging (MRI) using gadoteric acid (Gd-DOTA, Dotarem(®), Guerbet, Roissy CdG, France) as IV contrast medium (mean volume, 16.4 ml). 22.9% of the patients had at least one risk factor (e.g., allergies, previous allergic reaction to a contrast medium, and renal impairment). 554 patients received pretreatment before contrast medium administration (0.7%). Adverse events were documented and image quality was assessed. RESULTS: A diagnosis was possible in 99.7% of all cases. Image quality was rated good or excellent in 97.1%. Adverse events (e.g., nausea, vomiting, and urticaria) were observed in 0.34% of the examinations and were mostly rated as minor. There were 8 patients with serious adverse events. The adverse event rate was significantly higher in patients with a history of allergies (0.62%; p<0.001) and in patients with a previous allergic reaction to contrast medium (1.23%; p<0.001). There was no elevated incidence of adverse events in patients with renal impairment. CONCLUSION:Gadoteric acid is a well-tolerated MRI contrast medium in patients with and without risk factors that is associated with a low rate of adverse events and good or excellent image quality in most patients.
Authors: Arnaud Attyé; G Dumas; I Troprès; M Roustit; A Karkas; E Banciu; J Pietras; L Lamalle; S Schmerber; A Krainik Journal: Eur Radiol Date: 2015-03-28 Impact factor: 5.315
Authors: Martin R Prince; Hae Giu Lee; Chang-Hee Lee; Sung Won Youn; In Ho Lee; Woong Yoon; Benqiang Yang; Haiping Wang; Jin Wang; Tiffany Ting-Fang Shih; Guo-Shu Huang; Jiing-Feng Lirng; Petra Palkowitsch Journal: Eur Radiol Date: 2016-03-09 Impact factor: 5.315
Authors: Won-Jin Moon; Young Ah Cho; Seok Hahn; Hye Min Son; Sung Koo Woo; Young Han Lee Journal: Contrast Media Mol Imaging Date: 2021-10-31 Impact factor: 3.161
Authors: Gilbert Deray; Olivier Rouviere; Lorenzo Bacigalupo; Bart Maes; Thierry Hannedouche; François Vrtovsnik; Claire Rigothier; Jean-Marie Billiouw; Paolo Campioni; Joaquin Ferreiros; Daniel Devos; Daniel Alison; François Glowacki; Jean-Jacques Boffa; Luis Marti-Bonmati Journal: Eur Radiol Date: 2012-12-05 Impact factor: 5.315